Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (34)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119

    HIV Medicine, Vol. 24, Núm. 8, pp. 933-937

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)

    PLoS ONE, Vol. 17, Núm. 12 December

2021

  1. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis

    Clinical Microbiology and Infection

  2. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

    Gastroenterology, Vol. 155, Núm. 4, pp. 1120-1127.e4

  2. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort

    Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706

  3. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

    HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30

2017

  1. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 5, pp. 853-861

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain

    HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65

  2. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  3. Current epidemiology and outcome of infective endocarditis: A multicenter, prospective, cohort study

    Medicine (United States), Vol. 94, Núm. 43